Tecentriq-Avastin combo poised to become SOC for hepatocellular carcinoma

Tecentriq continues to carve out a niche in the crowded PD-1/PD-L1 space as new survival data for the drug in the combination with Avastin in hepatocellular carcinoma pave the way for the regimen to become standard of care.

On Friday, Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit unveiled data from the Phase III IMbrave150

Read the full 540 word article

User Sign In